Adelaide, Australia, 23 November 2015 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, confirms in accordance with Listing Rule 3.13.2, the results for each of the resolutions put to the Annual General Meeting held at 2:00 pm on Wednesday 23 November 2016 was as follows:

Ordinary Business

Resolution 2 – Re-election of Rahmon Coupe as a Director

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

<table>
<thead>
<tr>
<th></th>
<th>For</th>
<th>Against</th>
<th>Open Proxies</th>
<th>Abstain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>40,517,312</td>
<td>202,436</td>
<td>683,472</td>
<td>46,259</td>
</tr>
</tbody>
</table>

Result: Resolution Carried by a show of hands

Resolution 3 – Ratification of Prior Share Issue Placement for Purpose of Listing Rule 7.4: Reset of 15% Threshold

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

<table>
<thead>
<tr>
<th></th>
<th>For</th>
<th>Against</th>
<th>Open usable</th>
<th>Abstain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24,473,158</td>
<td>231,442</td>
<td>680,472</td>
<td>86,995</td>
</tr>
</tbody>
</table>

Result: Resolution Carried by a show of hands
Resolution 4 – Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

<table>
<thead>
<tr>
<th></th>
<th>For</th>
<th>Against</th>
<th>Open proxies</th>
<th>Abstain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Resolution Carried by a show of hands</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Meeting closed at 3:10 pm

Maria Maieli
CFO & Company Secretary

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative product that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5293 | M +61 417 818 658
tspurling@ellex.com

Andrew Angus, Investor Relations
Overland Advisors 0402 823 757
andrewangus@overlandadvisers.com.au

Maria Maieli, CFO & Company Secretary
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5200
mmaieli@ellex.com